肺癌

有意团购印度易瑞沙 印度特罗凯 印度力比泰 请加入我们的群
官方QQ群:26438631  5100806 或 QQ:3 5 7 6 8 7 5

　　广东专家联手美国哈佛大学,找到了肺癌靶向治疗(印度易瑞沙 印度特罗凯 印度力比泰 )的耐药(易瑞沙耐药后的治疗方法)基因,使治疗有效率从71%提高到93%,标志着肿瘤治疗进入全基因时代。

　　昨天,中国抗癌协会肺癌专业委员会主任委员、广东省人民医院副院长吴一龙教授高兴地说,广东省人民医院与美国哈佛大学、麻省总医院合作完成的上述科研项目在2010年1月的《癌细胞》(CANCERCELL)杂志上发表。

　　吴一龙指出,研究发现,30%的亚洲肺癌病人、10%的欧洲病人的“人体表皮细胞生长因子受体”发生了基因突变,这部分病人如果接受分子靶向治疗,有效率达到71%,因此,分子靶向治疗被认为是特异性非常高的个体化治疗手段。然而,在临床中,仍有近三成的病人使用了目前国际上最先进的分子靶向治疗药物却没有效果。

　　2009年起,美国哈佛大学、麻省总医院邀请广东省人民医院一起开展科研项目,找出靶向治疗耐药的原因。省医在该项科研中,贡献了30%的临床病例。研究人员发现,在耐药的病人中,发现了一个叫MET的基因,后者被靶向治疗药物激活并产生耐药。研究人员发现,如果用药抑制MET基因的扩增,可以使肺癌靶向治疗的有效率从71%提高到93%。

看过此文章的朋友还看过
易瑞沙耐药后的治疗方法          易瑞沙(IRESSA)中文说明
力比泰(ALIMTA)中文说明书       最近小心有人卖假印度易瑞沙

==== 汉译英 ====

Guangdong, together experts from Harvard University, found a lung cancer targeted therapy (Iressa India India India Alimta Tarceva) resistance gene, so that the efficiency of treatment from 71% to 93%, marking the tumor treatment into the full - GeneScan.

Yesterday, the Chinese Anti-Cancer Association, lung cancer, chairman of the Professional Committee of the Guangdong Provincial People's Hospital, vice president of Professor Wu Yilong pleased to say, the Guangdong Provincial People's Hospital and Harvard University, Massachusetts General Hospital, completed in cooperation in the above-mentioned research project in January 2010 of the "cancer" (CANCERCELL) published in the journal.

Wu Long pointed out that the study found that 30% of the Asian lung cancer patients, 10% of the sick man of Europe "human epidermal growth factor receptor," gene mutation occurred in this part of the molecular target therapy if patients are receiving, there is efficiency of 71%, so , molecular targeted therapy is considered a very high specificity of individual treatment. However, in clinical practice, there are still Jinsan Cheng patients to use the current world's most advanced molecular targeted therapies have no effect.

In 2009, the United States Harvard University, Massachusetts General Hospital, Guangdong Provincial People's Hospital, together with the invitation to carry out scientific research projects to identify the reasons for resistance to targeted therapy. Medical and scientific research in the province contributed 30% of clinical cases. The researchers found that in drug-resistant patients, found a gene called MET, which was targeted to activate and become resistant to treatment. The researchers found that if the drugs inhibit MET gene amplification will enable the efficient targeted therapy of lung cancer from 71% to 93%.